ALK and non-small cell lung carcinoma: Bauer Bauer TM TM Shaw Shaw AT AT Johnson Johnson ML ML Navarro Navarro A A Gainor Gainor JF JF Thurm Thurm H H Brain penetration of Lorlatinib: cumulative Incidences of CNS and non-CNS progression with Lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer Brain penetration of Lorlatinib: cumulative Incidences of CNS and non-CNS progression with Lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer Target Oncol Target Oncol 2020 2020 15 15 1 1 55 55 65 65 10.1007/s11523-020-00702-4 10.1007/s11523-020-00702-4 32060867 32060867